Blujepa offers a new treatment option amid rising antibiotic resistance
US health regulators have approved a new antibiotic for urinary tract infections (UTIs), marking a significant advancement in the fight against drug-resistant bacteria. British pharmaceutical company GSK announced Tuesday that the US Food and Drug Administration (FDA) has given the green light for Blujepa, a treatment for uncomplicated UTIs in adult women and girls aged 12 and older.
First in a new class of oral antibiotics
Blujepa is the first of a new class of oral antibiotics designed specifically to treat urinary tract infections, a condition affecting more than 100 million people worldwide, primarily women.
GSK’s chief scientific officer, Tony Wood, hailed the FDA’s approval as a “crucial milestone,” emphasizing the drug’s potential to provide an alternative treatment option.
“While existing antibiotics are available, this new medication offers another choice for patients who experience recurrent infections and face rising resistance to current treatments,” Wood said.
Addressing growing antibiotic resistance
The overuse of antibiotics has contributed to the rise of drug-resistant bacteria, making UTIs increasingly difficult to treat. A 2019 study found that 92% of bacteria responsible for UTIs were resistant to at least one antibiotic, while 80% showed resistance to two or more.
With the approval of Blujepa, health experts hope to improve treatment options for patients struggling with persistent infections while tackling the growing challenge of antibiotic resistance.
